STAAR Surgical Company (NASDAQ: STAA) announced preliminary net sales exceeding $90 million for the first quarter ended April 3, 2026, compared to $42.6 million in the same period last year.

The company attributed the majority of the sales increase to strong performance in China, its largest market, along with continued double-digit growth in the Americas. STAAR manufactures implantable collamer lenses for vision correction.

"We are very pleased with our strong first quarter net sales in our largest market, China, which accounted for the majority of the increase in net sales, along with continued double-digit growth in the Americas," said Deborah Andrews, Interim Co-CEO and CFO.

The company noted that net sales in the Middle East and parts of the EMEA and APAC regions declined due to geopolitical and macroeconomic challenges. STAAR cautioned that sales growth could continue to be affected if these conditions persist.

The first quarter 2025 results were impacted as the company shipped minimal quantities to China while distributors worked through excess inventory. As of the end of the first quarter 2026, distributor inventory appears to be within the company's targeted range.

Andrews stated that the higher net sales, combined with improved cost structure, are expected to drive meaningful improvement in adjusted EBITDA for the quarter. The company continues to provide no forward revenue or earnings guidance.

STAAR plans to release full first quarter financial results and file its 10-Q report in early May. The preliminary financial information is unaudited and subject to adjustment as the company completes its quarterly review.